{"id":8518,"date":"2021-12-17T01:44:18","date_gmt":"2021-12-17T06:44:18","guid":{"rendered":"https:\/\/puyapeptide.net\/product\/liraglutid-cas-204656-20-2-til-vaegttab-og-behandling-for-type-2-diabetes\/"},"modified":"2021-12-17T01:44:18","modified_gmt":"2021-12-17T06:44:18","slug":"liraglutid-cas-204656-20-2-til-vaegttab-og-behandling-for-type-2-diabetes","status":"publish","type":"product","link":"https:\/\/puyapeptide.net\/da\/product\/liraglutid-cas-204656-20-2-til-vaegttab-og-behandling-for-type-2-diabetes\/","title":{"rendered":"Liraglutid CAS 204656-20-2 til v\u00e6gttab og behandling for type 2-diabetes"},"content":{"rendered":"

Liraglutid CAS 204656-20-2 til v\u00e6gttab og behandling for type 2-diabetes<\/strong><\/h2>\n

Produktnavn: Liraglutide
\nSynonymer: Liraglutide;Glycin, L-histidyl-L-alanyl-L-alfa-glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-alfa- aspartyl-L-valyl-L-seryl-L-seryl-L-tyrosyl-L-leucyl-L-alfa-glutamylglycyl-L-glutaminyl-L-alanyl-L-alanyl-N6-(N-(1-oxohexadecyl) -L-gamma-glutamyl)-L-lysyl-L-alfa-glutamyl-L-phenylalanyl-L-isoleucyl-L-alanyl-L-tryptophyl-L-leucyl-L-valyl-L-arginylglycyl-L-arginyl- ;Liraglutida;Liraglutida [kro-spansk];Liraglutide [usan:inn];Liraglutidum;Liraglutidum [inn-latin];N26-(Hexadecanoyl-gamma-glutamyle)-(34-arginin)glp-1-(7-37) -peptid
\nCAS: 204656-20-2
\nMF: C172H265N43O51
\nMW: 3751.202
\nEINECS: 810-818-7
\nProduktkategorier: GLP
\nMol Fil: 204656-204656 -2.mol<\/p>\n

Liraglutid er en klar, farvel\u00f8s opl\u00f8sning. Doseringsformen er subkutan injektion. Efter mere end 10 \u00e5rs forskning og udvikling har Liraglutid mange funktioner, s\u00e5som at fremme regenerering af \u00f8celler, s\u00e6nke blodsukkeret, reducere v\u00e6gten og beskytte det kardiovaskul\u00e6re system. Varem\u00e6rket Victoza bruges til at behandle type 2-diabetes, og varem\u00e6rket Saxenda bruges til at behandle kronisk fedme. Som et supplement til kostkontrol og fysisk tr\u00e6ning. Liraglutid er en acyleret human glucagon-lignende peptid-1 (GLP-1) receptoragonist, som har 97 % aminosyresekvenshomologi med humant endogen GChemicalbookLP-1 (7-37), og bevarer den har alle de biologiske aktiviteter af GLP- 1 og har GLP-1-receptoragonisme. Gennem ekspressionen af rekombinant DNA i Saccharomyces cerevisiae er dens molekyl\u00e6re struktur kun \u00e9n aminosyreforskel fra det naturlige GLP-1-molekyle. Strukturen modificerer kun f\u00f8lgende to dele af GLP-1: det vil sige, at den 34. lysin er erstattet af arginin. Syresubstitution, udover at tilf\u00f8je en glutaminsyre-medieret 16-carbon palmitoylfedtsyresidek\u00e6de p\u00e5 den 26. lysin.<\/p>\n

Funktion af Liraglutid CAS 204656-20-2<\/strong> <\/p>\n

1.Det virker p\u00e5 en glucoseafh\u00e6ngig m\u00e5de, hvilket betyder, at det kun vil stimulere insulinsekretion, n\u00e5r blodsukkerniveauet er h\u00f8jere end normalt, hvilket forhindrer ""overshoot"". F\u00f8lgelig viser det en ubetydelig risiko for hypoglyk\u00e6mi.
\n2.Det har potentiale til at h\u00e6mme apoptose og stimulere regenerering af betaceller (set i dyrefors\u00f8g).
\n3.Det mindsker appetitten og h\u00e6mmer v\u00e6gt\u00f8gning, som vist. i en hoved-til-hoved unders\u00f8gelse versus glimepirid.
\n4.Det s\u00e6nker blodets triglyceridniveauer.<\/p>\n

Anvendelse af Liraglutid CAS 204656-20-2<\/strong>
\n1.Behandling af type 2-diabetes.
\n 2.Behandling af fedme.<\/p>\n","protected":false},"excerpt":{"rendered":"

Produktnavn: Liraglutide
\nCAS: 204656-20-2
\nMF: C172H265N43O51
\nMW: 3751.202
\nEINECS: 810-818-7
\nProduktkategorier: GLP
\nMol Fil: 2 -20-2 mol<\/p>\n","protected":false},"featured_media":2119,"comment_status":"open","ping_status":"closed","template":"","meta":{"om_disable_all_campaigns":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"site-sidebar-layout":"default","site-content-layout":"default","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}}},"product_brand":[],"product_cat":[338],"product_tag":[1211],"class_list":{"0":"post-8518","1":"product","2":"type-product","3":"status-publish","4":"has-post-thumbnail","6":"product_cat-diabetes-peptid","7":"product_tag-liraglutide-cas-204656-20-2-for-weight-loss-and-treat-for-type-2-diabetes-da","8":"desktop-align-left","9":"tablet-align-left","10":"mobile-align-left","12":"first","13":"instock","14":"shipping-taxable","15":"product-type-simple"},"_links":{"self":[{"href":"https:\/\/puyapeptide.net\/da\/wp-json\/wp\/v2\/product\/8518","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/puyapeptide.net\/da\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/puyapeptide.net\/da\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/puyapeptide.net\/da\/wp-json\/wp\/v2\/comments?post=8518"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/puyapeptide.net\/da\/wp-json\/wp\/v2\/media\/2119"}],"wp:attachment":[{"href":"https:\/\/puyapeptide.net\/da\/wp-json\/wp\/v2\/media?parent=8518"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/puyapeptide.net\/da\/wp-json\/wp\/v2\/product_brand?post=8518"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/puyapeptide.net\/da\/wp-json\/wp\/v2\/product_cat?post=8518"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/puyapeptide.net\/da\/wp-json\/wp\/v2\/product_tag?post=8518"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}